News Release



INCJ and 10 portfolio companies in the health and medical field to jointly exhibit at BioJapan 2016

Tokyo, September 26, 2016 – Innovation Network Corporation of Japan ("INCJ") announced today its decision to exhibit at Asia's leading partnering event in the biotechnology industry, BioJapan 2016, for 3 days between October 12 (Wed.) – 14 (Fri.) at Pacifico Yokohama.

In April 2014, INCJ established a new specialist team covering the health and medical field, which focuses on proactive investment in bio venture companies and supporting the formation and commercialization of ecosystems in this field. Since its establishment in 2009, INCJ has made a total of 106 investments, of this 84 were venture investments and 19 were in the health and medical field. (Figures are as of August 2016.)

INCJ also participated in this event last year and will co-exhibit in a similar capacity alongside its portfolio companies in the health and medical field as well as participating in partnering activities. Within the exhibition booth, INCJ will showcase panels and posters introducing each company's business outline and technology in order to increase the understanding and awareness of visitors. With regards to partnering, INCJ will explore new possibilities from the introduction of seeds, technology tie-ups and company alliances and conduct networking activities and business meetings.

INCJ will continue to focus on investment activities in the health and medical field and support the steady increase of the value of its portfolio companies and their businesses.

About BioJapan 2016

Event time and date October 12 (Wed.) -14 (Fri.) 2016

10:00 ~ 17:00 (Partnering from 8:45)

Location Pacifico Yokohama, Exhibition Hall B/C/D

1-1-1 Minato Mirai, Nishi-ku, Yokohama

Website http://www.ics-expo.jp/biojapan/main/index.html

INCJ exhibition booth location A-11

Co-exhibitors

- Innovation Network Corporation of Japan
- Aqua Therapeutics Co., Ltd. (Development of Japan-specific next generation nucleic acid drugs targeting periostin)



 Anaeropharma Science Co., Ltd. (Development of an anti-cancer Drug Delivery System (DDS) Anaeropharma Science originating from Shinshu University)

 Curadim Pharma Co., Ltd. (New drug development for intractable diseases)



 NanoMist Technologies Co., Ltd. (Development, manufacture and sales of ultrasonic mist separation **NAMtech** systems)



· NapaJen Pharma, Inc. (Development of nucleic acids using unique drug delivery technology)



· Embrace Co., Ltd. (A communication platform for an integrated community care system)



 PRISM Pharma Co., Ltd. (Development of therapeutic agents using a peptide imitation compound)




 Microwave Chemical Co., Ltd. (R&D, manufacture and sales including licensing of microwave chemical processes)



 Universal View Co., Ltd. (Development, manufacture and sales of ophthalmic medical WUNIVERSAL VIEW equipment)

Rena Therapeutics Inc.





About Innovation Network Corporation of Japan (INCJ)

INCJ was established in July 2009 as a public-private partnership that provides financial, technological and management support for next-generation businesses. INCJ specifically supports those projects that combine technologies and varied expertise across industries and materialize open innovation. INCJ has the capacity to invest up to ¥2 trillion (approx. US\$20 billion).

INCJ's management team is drawn from the private sector with diverse experience in investment, technologies and management. Through its Innovation Network Committee, INCJ assesses investment opportunities that contribute to industrial innovation in Japan in line with criteria set by the government.

Press contacts:

Innovation Network Corporation of Japan
Corporate Planning Group, Communications, Irie, Sakai
21st Floor, Marunouchi Eiraku Building
1-4-1 Marunouchi, Chiyoda-ku, Tokyo
Tel. (03) 5218-7202

URL: http://www.incj.co.jp/